For more information, availability and pricing options for sponsorship/exhibition opportunities at the event, please contact Jon Liong at email@example.com.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OAP has made PE investments in 29 companies, with close to USD$500 million under management. OrbiMed has also invested over USD$1 billion in the stocks of Asia public healthcare companies. For More information, please vist www.orbimed.com.
FOUNTAIN MEDICAL DEVELOPMENT
Fountain Medical Development Ltd. is a contract research organization (CRO) dedicated to offering a full range of ICH GCP compliant clinical research services for multinational clients conducting clinical research in China and United States, Europe, Japan, Australia, Taiwan and other countries & regions including Regulatory Affairs, Phase I-IV clinical trials, Data Management and Biostatistics, Project Management, Medical Writing, Medical Translation, Safety Handling, Consulting and Pharmacoeconomic studies. The FMD management team has decades of combined experience working with the world’s leading CROs and drug developers. Our extensive global experience in multiple therapeutic areas is unmatched by other local CROs, and our lower operational cost allows us to pass significant savings on to our clients. Fountain has hands-on clinical trial experiences in mainland of China, Hong Kong, Taiwan, Korea, Japan, Armenia and the US, and has completed more than 200 clinical trial projects, we have been in good partnership with more than 300 sites in Asia and we have enrolled more than 80000 patients in clinical trials. Fountain’s success includes the excellent team, the strategic capability and undertaking pivotal international studies. Fountain is your trustworthy CRO Choice.
PRA HEALTH SCIENCES
PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Our people love what they do, working tirelessly for clients across all phases and therapeutic areas. With 12,000+ employees covering 80+ countries, we provide an impressive global presence and in-depth knowledge of local regulations, standards of care and cultural customs.
PRA’s Strategic Solutions Division (formerly known as “RPS”) maintains a sole focus on delivering practical, customized outsourcing solutions that seamlessly enhance our clients’ infrastructure. Our unique Embedded Solutions™ model provides people, processes, systems and expertise to efficiently develop internal product portfolios, enhance quality and improve efficiency, while sponsors maintain strategic control.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 53 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 2000 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 500 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 58 innovative drugs.
For more information about Tigermed, please visit www.tigermed.net